INDRAMEDCO · Indraprastha Medical Corporation Ltd · Healthcare Facilities
INDRAMEDCO · Indraprastha Medical Corporation Ltd · Healthcare Facilities
As of 06 Nov close
52-week range
48.5% below 52-week high
52-week range: as of 06 Nov 2026 close.
Price chartDaily closes on the stock page.
Weighted combination of 8 measured readings. Not a probability, a rating or a forecast.
Full signal detail →Fundamentals as of 15 Sep 2026 · the company's own latest record is 53 days old
Revenue (latest Q)
₹406 Cr
Revenue YoY
PAT YoY
+8.5%
Operating margin
Revenue, last 8 quarters
P/E (TTM)
P/B
4.4
P/S (TTM)
2.1
Sector P/E
29.7
Dividend yield
+1.1%
| Company | P/E | P/B | Net margin | ROE | D/E | Div. yield |
|---|---|---|---|---|---|---|
| INDRAMEDCO (this stock) | 18.9 | 4.4 | +12.3% | +25.4% | 0.05 | +1.1% |
| Apollo Hospitals Enterprise | 64.9 | 13.4 | +7.8% | +21.9% | 53.8 | +0.2% |
| Max Healthcare Institute | 71.5 | 9.9 | +17.2% | +14.3% | 27.71 | +0.2% |
| Fortis Healthcare | 69 | 14.6 | +11.0% | +10.6% | 0.35 | +0.1% |
Promoter
stable
FII
rising 1q
MF
0.01% (0.00pp)
stable
Insider trades
No insider trades in the last 12 months.
Bulk/block deals
No bulk/block deals in the last 12 months.
News timeline
No related news.
Concalls & investor presentations
AI-generatedNo concall transcripts or investor presentations recorded yet.
AI Summary of Annual Report
AI-generatedIndraprastha Medical Corporation Limited (IMCL) emphasizes its role in India's evolving healthcare landscape, focusing on integrated, technology-enabled services and clinical excellence. The report highlights strategic priorities such as expanding medical tourism, enhancing digital health platforms, and addressing non-communicable diseases through early detection and personalized care. IMCL also underscores its commitment to corporate governance, sustainability, and community engagement, while acknowledging risks related to regulatory changes, competition, and operational challenges.
- Focus on integrated, technology-enabled healthcare services and clinical excellence across specialties like cardiac care and oncology.
- Expansion of medical tourism and digital health platforms to improve accessibility and affordability.
- Commitment to corporate governance, sustainability, and community engagement initiatives.
- Strategic emphasis on preventive care, early detection, and personalized treatment for non-communicable diseases.
- Investment in infection control, staff training, and patient-centric care to enhance service quality and safety.
Key takeaway: Indraprastha Medical Corporation Limited is positioning itself as a leader in India's healthcare sector through integrated, technology-driven services, clinical excellence, and a strong focus on sustainability and patient-centric care.
The following annual report excerpts provide qualitative strategic context. Do not treat any specific financial figures in these excerpts as authoritative — they may be incorrectly labeled due to PDF table extraction limitations. For precise financial data, refer to the structured fundamentals data above.
Governance disclosures
AI-generatedNeeds attention
No item of a kind that needs attention was stored for this company.
Contingent Liability
1 occurrenceEarlier (1-3 years ago)
The company has contingent liabilities from litigative matters, including a significant matter regarding free treatment of underprivileged patients as per the lease deed with the Delhi Government, which may have a significant impact on the company's operations.
Related-Party Transaction
1 occurrenceEarlier (1-3 years ago)
Indraprastha Medical Corporation Limited has disclosed related party transactions with entities such as Apollo Hospitals Enterprise Limited, Sindoori Management Solutions Private Limited, Apollo Sindoori Hotels Limited, Apollo Healthco Limited, Keimed Private Limited, and Medvarsity Online Limited, involving transactions like purchase of services, license fees, commission on pharmacy sales, dividend paid, reimbursement of expenses, and trade payable.
Promoter Share Pledge
1 occurrenceRecent (last 12 months)
6.9% of promoter holding pledged (quarter 2026-Q3 as of 2026-07-18).